93. De Matteis, S.; Ragusa, A.; Marisi, G.; De Domenico, S.; Casadei Gardini, A.; Bonafè, M.; Giudetti, A.M. Aberrant Metabolism in Hepatocellular Carcinoma Provides Diagnostic and Therapeutic Opportunities. *Oxid. Med. Cell Longev.* **2018**, *2018*, 7512159. [CrossRef]

94. Baenke, F.; Peck, B.; Miess, H.; Schulze, A. Hooked on fat: The role of lipid synthesis in cancer metabolism and tumour development. *Dis. Model. Mech.* **2013**, *6*, 1353–1363. [CrossRef]

95. Lincet, H.; Icard, P. How do glycolytic enzymes favour cancer cell proliferation by nonmetabolic functions? *Oncogene* **2015**, *34*, 3751–3759. [CrossRef]

96. Lhan, M. Non-metabolic functions of Pyruvate kinase M2: PKM2 in tumorigenesis and therapy resistance. *Neoplasma* **2022**, *69*, 747–754.

97. Huang, C.K.; Sun, Y.; Lv, L.; Ping, Y. ENO1 and Cancer. *Mol. Ther. Oncol.* **2022**, *24*, 288–298. [CrossRef]

98. Gurung, S.; Chung, K.P.S.; Lee, T.K.-W. Emerging role of fatty acid binding proteins in cancer pathogenesis. *Histol. Histopathol.* **2019**, *34*, 1–12.

99. Conte, M.; Franceschi, C.; Sandri, M.; Salvioli, S. Perilipin 2 and Age-Related Metabolic Diseases: A New Perspective. *Trends Endocrinol. Metab.* **2016**, *27*, 893–903. [CrossRef]

100. Miyata, Y.; Sakai, H. Thrombospondin-1 in Urological Cancer: Pathological Role, Clinical Significance, and Therapeutic Prospects. *Int. J. Mol. Sci.* **2013**, *14*, 12249–12272. [CrossRef]

101. Lawler, P.; Lawler, J. Molecular Basis for the Regulation of Angiogenesis by Thrombospondin-1 and -2. *Cold Spring Harb. Perspect. Med.* **2012**, *2*, a006627. [CrossRef] [PubMed]

102. Poon, R.T.; Chung, K.K.; Cheung, S.T.; Lau, C.P.; Tong, S.W.; Leung, K.L.; Yu, W.C.; Tuszynski, G.P.; Fan, S.T. Clinical Significance of Thrombospondin 1 Expression in Hepatocellular Carcinoma. *Clin. Cancer Res.* **2004**, *10*, 4150–4157. [CrossRef] [PubMed]

103. Li, Y.; Turpin, C.P.; Wang, S. Role of thrombospondin 1 in liver diseases. *Hepatol. Res.* **2017**, *7*, 186–193. [CrossRef] [PubMed]

104. Zhang, X.; Lawler, J. Thrombospondin-based antiangiogenic therapy. *Microvasc. Res.* **2007**, *74*, 90–99. [CrossRef]

105. Chen, R.; Tan, Y.; Wang, M.; Wang, F.; Yao, Z.; Dong, L.; Ye, M.; Wang, H.; Zou, H. Development of Glycoprotein Capture-Based Label-Free Method for the High-throughput Screening of Differential Glycoproteins in Hepatocellular Carcinoma. *Mol. Cell. Proteom.* **2011**, *10*, 06445. [CrossRef]

106. Chavez-Tapia, N.C.; Rosso, N.; Tiribelli, C. Effect of intracellular lipid accumulation in a new model of non-alcoholic fatty liver disease. *BMC Gastroenterol.* **2012**, *12*, 20. [CrossRef]

107. Zhang, L.; Yang, P.; Wang, J.; Liu, Q.; Wang, T.; Wang, Y.; Lin, F. MiR-22 regulated T cell differentiation and hepatocellular carcinoma growth by directly targeting Jarid2. *Am. J. Cancer Res.* **2021**, *11*, 2159–2173.

108. Mah, S.M.; Buske, C.; Humphries, R.K.; Kuchenbauer, F. miRNA*: A passenger stranded in RNA-induced silencing complex? *Crit. Rev. Eukaryot. Gene Expr.* **2010**, *20*, 141–148. [CrossRef]

109. Calo, N.; Ramadori, P.; Sobolewski, C.; Romero, Y.; Maeder, C.; Fournier, M.; Rantakari, P.; Zhang, F.P.; Poutanen, M.; Dufour, J.F.; et al. Stress-activated miR-21/miR-21* in hepatocytes promotes lipid and glucose metabolic disorders associated with high-fat diet consumption. *Gut* **2016**, *65*, 1871–1881. [CrossRef]